Skip to main content
padlock icon - secure page this page is secure

Recent Advances in PDE4 Inhibitors as Immunoregulators and Antiinflammatory Drugs

Buy Article:

$68.00 + tax (Refund Policy)

The phosphodiesterases (PDEs) are responsible for the hydrolysis of intracellular cyclic adenosine and guanosine monophosphate (cAMP and cGMP, respectively). They are classified into 11 major families (PDE1-11) and the type 4 phosphodiesterase (PDE4) is a cAMP-specific enzyme localized in airway smooth muscle cells as well as in immune and inflammatory cells. The PDE4 activity is associated with a wide variety of diseases some of which have been related to an inflammatory state, (e.g. asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA)) while others have recently been connected to autoimmune pathology. Therefore, an intense effort toward the development of PDE4 inhibitors has been generated for the last decade. Unfortunately, the effects of prototype PDE4 inhibitors have been compromised by side effects such as nausea and emesis and the clinical use of those compounds is still limited. Several companies have focused on the design of a new generation of PDE4 inhibitors dissociating beneficial activity and adverse effects. This review updates a previous article [1]. It highlights the recent data of the most advanced clinical candidates, the design and structure activity relationships of the recent structural series reported in the literature over the last three and half years, as well as recent advances in the multiple therapeutic indications of PDE4 inhibitors (a review with more than 500 references).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: PDE4 Inhibitors; inflammatory cells; monophosphate; phosphodiesterase

Document Type: Review Article

Affiliations: 13 rue de 1'Ermitage, 91390 Morsang sur Orge, France.

Publication date: January 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more